EN DE
Data-driven stock valuation

Raia Drogasil SA ADR (RADLY) fair value: what the stock is really worth

We calculate from audited financials what Raia Drogasil SA ADR is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

  1. Compare price with fair valuebelow fair value = cheap, above = expensive
  2. Check the quality50 and up solid, 75 and up strong
  3. Watch it or check another stockalert when fair value or trend changes

Healthcare · US · Market cap $5.8B · ISIN US7507231089

At a glance

RD Raia Drogasil SA ADR logo Raia Drogasil SA ADR RADLY · US
Price$3.85
Fair Value$2.40
Upside−37.7%
Quality53/100

A solid business, but trading 60% above our fair value of $2.40.

As of Sep 3, 2026, the fair value of Raia Drogasil SA ADR is $2.40 per share against a price of $3.85, so the fair value sits 38% below the price. A model estimate from reported figures, not an analyst target.

✓Healthy Growth (revenue 5y +16.7 %/yr)
!Thin margins · 2.8% net margin
✓Low debt · generates free cash flow
·2.34% dividend yield
✓Ranks above peers (9/14)
!Moderate moat 47/100
Evidence: High Range $2.03 to $3.71

Fair value as of: Sep 3, 2026

From 26 valuation models · updated 5 days ago

Fair value updated Sep 3, 2026, revised from $2.38 to $2.40 (+0.8%) since Aug 13, 2026. Share price −3.6% over the past month.

Watch Raia Drogasil SA ADR for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case ($3.71). The favourable scenario is already priced in.
  • Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
  • A fairly wide model range ($2.03 to $3.71) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

$7.49 $2.33 Fair Value $2.40 Oct 2018 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 3, 2026.

How to read this chart

60‑month range $2.33 – $7.49 · fair‑value band $2.03 – $3.71 · the $3.85 price screens above the $2.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 3, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Raia Drogasil SA ADR (RADLY) currently trades at $3.85, while our model-based Fair Value estimate is $2.40, implying the stock looks roughly 60.4% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of $22.97 per share, and 25 of the 26 models we run sit above the $3.85 price. Bear case: the Asset-Based group reads lowest at $2.80, and 1 of the 26 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Raia Drogasil SA ADR generated revenue of $45.5B at a net margin of 2.8%. Revenue grew 14.0% year over year. It earns a return on equity of 18.9%. Net debt stands at $8.3B. Fundamentals as of Sep 3, 2026

Scenario range: $2.03 (bear) to $3.71 (bull), the price of $3.85 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 26% below its 52-week high and 65% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −23% fair-value upside, at −38%, RADLY screens richer than that median.

Fair Value models

Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF $7.05 $12.48 $27.90 74
EPV $10.47 $12.38 $14.03 74
Growth DCF $6.61 $13.84 $27.28 74
All 26 models by family
DCF Models
FCF DCF $7.05 $12.48 $27.90 74
Owner Earnings $14.25 $33.55 $72.60 70
5Y Revenue Exit $10.90 $22.97 $46.84 68
5Y EBITDA Exit $18.54 $39.40 $78.03 70
5Y P/E Exit $8.84 $20.68 $36.03 67
10Y Revenue Exit $9.14 $23.21 $39.93 63
10Y EBITDA Exit $14.95 $37.52 $80.48 63
10Y P/E Exit $8.25 $19.36 $38.73 59
Earnings-Based
Graham-Dodd $4.94 $34.48 $48.39 63
Lynch FV $10.48 $14.97 $19.46 61
PEG = 1.0 $10.48 $14.97 $19.46 57
EPV $10.47 $12.38 $14.03 74
Dividend Discount
Gordon GGM $3.21 $6.40 $9.70 67
DDM Multi-Stage $3.21 $5.54 $6.76 67
Multiples
P/E Multiple $11.45 $15.27 $19.09 63
P/S Multiple $9.27 $12.36 $15.45 58
P/B Multiple $9.27 $12.36 $15.45 55
EV/EBIT $17.22 $23.51 $29.79 66
EV/EBITDA $23.79 $32.27 $40.74 67
EV/Revenue $11.83 $17.59 $23.36 53
Asset-Based
NCAV (Graham) $2.09 $2.80 $4.19 54
Growth DCF
Growth DCF $6.61 $13.84 $27.28 74
Rev-Margin DCF $10.90 $24.65 $45.39 69
Economic Profit
Residual Income $4.58 $5.85 $15.59 67
ROIC Compounder $13.37 $19.97 $29.08 70
Growth Earnings
Growth-Adj P/E $14.21 $20.30 $26.39 67

Widest divergence: DCF Models ($22.97) versus Asset-Based ($2.80). Highest evidence: FCF DCF (74).

Notify me when RADLY reaches fair value

Put RADLY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 25.7
P/S ratio 0.75 P/E × margin
EPS (TTM) $0.1500 price ÷ EPS = P/E 25.7
Dividend yield 2.3% payout 60.1%
Net margin 2.9% FY2025
Return on equity 18.9% TTM
More key figures
Profitability
Return on assets (EBIT) 9.6% avg 5y
Operating margin 4.3% TTM
Growth
Revenue (TTM) $45.5B TTM
Revenue growth (YoY) +14.0% 3y avg +14.3%
EPS growth (YoY) −3.4%
Balance sheet & cash flow
Free cash flow $1.0B FY2025
Net debt $8.3B FY2025 · ≈ 8.3 yrs of FCF

Figures from reported company fundamentals · as of Sep 3, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 53/100

Of which business quality 53 · Market factors (momentum, volatility) 52

Profitability 61
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 40
Earnings quality: real cash, not paper profit
Fin. Strength 42
Balance sheet, leverage, solvency risk
Investment 56
Disciplined investing over empire-building
Low Volatility 57
Calm price path (market factor)
Momentum 47
Price trend over the last 3–12 months (market factor)
52W Momentum 54
Distance to the 52-week high (market factor)
Net Issuance 87
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. The company sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Raia Drogasil SA ADR reported revenue of R$43.4B in FY2025 versus R$24.1B in FY2021, a compound +15.8%/yr. Reported net income was R$1.3B in FY2025, compounding +14.0%/yr from FY2021.

Growth Quality 90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
$43.4B
Latest YoY
+11.6%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+14.3%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+16.7%
Avg. revenue growth/yr (22Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+24.6%
Value creation/yr (5Y, in BRL) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year. Measured in BRL: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+14.2%
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share+11.9%
Dividend yield2.3%
Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y 11.9% vs 10Y 14.5%, steady
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4.3% (2020) → 6.0% (2025) · rising
Worst earnings drop47% (2008) · in USD
Revenue +15.8%/yr
FY21 R$24.1B
FY22 R$29.1B
FY23 R$34.0B
FY24 R$38.9B
FY25 R$43.4B
Net income +14.0%/yr
FY21 R$752M
FY22 R$996M
FY23 R$1.1B
FY24 R$1.2B
FY25 R$1.3B
Character of growth · EPS growth decomposed (2014-2025) +15.2 % p.a.
Revenue per share +17.7 %

of which total revenue +17.3 % · buybacks/dilution +0.3 %

EBIT margin +4.7 %
Tax rate +1.7 %
Residual (interest, one-offs) −8.0 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

RADLY screens 60% overvalued. Compare with JD Health International Inc →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Raia Drogasil SA ADR · Fair Value
$2.40 −60%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Raia Drogasil SA ADR Fair Value". https://www.fairvalue-calculator.com/stock/RADLY

Earlier news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Pharmaceutical Retailers · 58 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation
Quality Score 53 · Above median
Fair Value upside −40% · Below median
Profitability
Return on equity (TTM) 19% · Top 25%
Return on assets 7% · Top 25%
Net margin (TTM) 3% · Above median
Operating margin (TTM) 4% · Above median
Growth and dividend
Revenue growth 14% · Above median
Dividend yield (TTM) 2.3% · Below median
Balance sheet
Debt / equity 0.46× · Highest 25%

Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper

P/E (TTM) 25.7× · Pricier than median
P/B 0.80× · Cheaper than median
P/S (TTM) 0.13× · Cheapest 25%
P/FCF 5.8× · Priciest 25%
EV/EBITDA 2.5× · Cheapest 25%

What the price implies (reverse DCF)

The inverse question: what free-cash-flow growth must Raia Drogasil SA ADR deliver for ten years so that today's price is fair in our DCF model? Same formula, same discount rate as the fair value.

Implied FCF growth, 10 years-4.5 % per year
Achieved revenue growth, 5 years+16.7 % p.a.
Sector median revenue growth+3.0 %
FCF yield on price15.78 %
Discount rate (WACC) in the models8.5 %

The price demands less growth than the company recently delivered: even a weaker business would justify the price. Ranking of the largest stocks →

Context: sector, industry, market

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 20
FUTURE70 · sector 21
PAST75 · sector 15
HEALTH77 · sector 98
DIVIDEND47 · sector 62

VALUE 0: the price sits above our fair-value range.

Insider activity: 45/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Sep 3, 2026).

Stock Price Fair Value vs Fair Value
JD Health International Inc 6618 HK$37.06 HK$33.39 −10%
Alibaba Health Information Technology Limited 0241 HK$3.26 HK$2.04 −37%
Yifeng Pharmacy Chain Co 603939 ¥22.90 ¥29.07 +27%
DaShenLin Pharmaceutical Group 603233 ¥18.79 ¥23.86 +27%
MedPlus Health Services Limited MEDPLUS ₹656.80 ₹191.97 −71%
LBX Pharmacy Chain Joint Stock Company 603883 ¥13.70 ¥10.57 −23%
Yixintang Pharmaceutical Group 002727 ¥11.61 ¥9.45 −19%
Anhui Huaren Health Pharmaceutical Co 301408 ¥16.31 ¥10.05 −38%
ShuYu Civilian Pharmacy Corp 301017 ¥13.30 ¥5.91 −56%
Apotea AB APOTEA kr 74.15 kr 46.46 −37%

Compare Raia Drogasil SA ADR with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Frequently asked questions

Is Raia Drogasil SA ADR (RADLY) overvalued or undervalued?
As of Sep 3, 2026, our model estimates a fair value of $2.40 versus a price of $3.85, about −38% upside (overvalued).
What is the fair value of RADLY?
Our model-based fair value for Raia Drogasil SA ADR is $2.40 (as of Sep 3, 2026), built from audited fundamentals. The current price: $3.85.
What is the quality score of RADLY?
Raia Drogasil SA ADR has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Raia Drogasil SA ADR (RADLY)?
Our model-based price target is the fair value of $2.40 (as of Sep 3, 2026) from 26 valuation models. Cautious scenario $2.03, optimistic scenario $3.71. It is a calculation from audited fundamentals, not an analyst target.
What is the Raia Drogasil SA ADR stock forecast for 2026?
Our models put fair value at $2.40, about −38% upside versus a price of $3.85 (overvalued). Cautious scenario $2.03, optimistic scenario $3.71. The calculation is refreshed regularly with new filings.
What is the revenue of Raia Drogasil SA ADR (RADLY)?
Raia Drogasil SA ADR reported trailing-twelve-month revenue of about $45.5B (latest available figure, as of Sep 3, 2026).
What is the net profit margin of RADLY?
The net profit margin of Raia Drogasil SA ADR is about 2.8%, meaning it keeps roughly 2.8% of revenue as net income. Based on the latest reported figures.
Does Raia Drogasil SA ADR pay a dividend?
Raia Drogasil SA ADR currently shows a dividend yield of about 2.34% relative to its recent price (as of Sep 3, 2026).
What growth is priced into Raia Drogasil SA ADR (RADLY)?
For today's price to be fair in a discounted-cash-flow model, Raia Drogasil SA ADR would have to grow free cash flow by -4.5 % per year for ten years (discount rate 8.5 %, then 2 % perpetual growth). Over the last 5 years revenue grew +16.7 % per year. As of Sep 3, 2026.
What discount rate (WACC) does the fair value of RADLY use?
Our models discount Raia Drogasil SA ADR at 8.5 %: a base by market capitalisation (mid), damped by beta 0.02, country premium for USA. The same rate applies in all 26 models.
Free · no account needed

Watch Raia Drogasil SA ADR in the live analysis

One click puts Raia Drogasil SA ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.